Scienture Holdings, Inc. (NASDAQ:SCNX) — Market Cap & Net Worth
Market Cap & Net Worth: Scienture Holdings, Inc. (SCNX)
Scienture Holdings, Inc. (NASDAQ:SCNX) has a market capitalization of $13.92 Million ($13.92 Million) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26288 globally and #5490 in its home market, demonstrating a -8.38% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Scienture Holdings, Inc.'s stock price $0.34 by its total outstanding shares 41064146 (41.06 Million). Also see SCNX total assets for a full breakdown of the balance sheet.
Scienture Holdings, Inc. Market Cap History: 2015 to 2026
Scienture Holdings, Inc.'s market capitalization history from 2015 to 2026. Data shows change from $422.10 Million to $13.92 Million (-26.21% CAGR). Also see cash efficiency ratio of Scienture Holdings, Inc. for how efficiently the company converts equity into cash flow.
Index Memberships
Scienture Holdings, Inc. is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #741 of 976 |
Weight: Scienture Holdings, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Scienture Holdings, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Scienture Holdings, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Scienture Holdings, Inc. for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
48.52x
Scienture Holdings, Inc.'s market cap is 48.52 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $176.51 Million | $2.48 Million | -$2.76 Million | 71.12x | N/A |
| 2017 | $172.67 Million | $2.93 Million | $288.98K | 58.91x | 597.53x |
| 2018 | $115.12 Million | $3.83 Million | $9.04K | 30.04x | 12737.25x |
| 2019 | $422.10 Million | $7.44 Million | -$284.43K | 56.76x | N/A |
| 2020 | $2.03 Billion | $17.12 Million | -$2.54 Million | 118.55x | N/A |
| 2021 | $905.59 Million | $9.89 Million | -$5.32 Million | 91.57x | N/A |
| 2022 | $154.64 Million | $10.25 Million | -$3.47 Million | 15.09x | N/A |
| 2023 | $132.92 Million | $1.36 Million | -$17.84 Million | 97.46x | N/A |
| 2024 | $248.44 Million | $136.64K | $9.07 Million | 1818.15x | 27.40x |
| 2025 | $20.94 Million | $431.61K | -$41.51 Million | 48.52x | N/A |
Competitor Companies of SCNX by Market Capitalization
Companies near Scienture Holdings, Inc. in the global market cap rankings as of September 16, 2026. Review how tangible is Scienture Holdings, Inc.'s equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Scienture Holdings, Inc. by market ranking:
- JD HEALTH INTL LTD (F:8ZN): Ranked #1929 globally with a market cap of $12.04 Billion USD ( €10.30 Billion EUR).
- Walgreens Boots Alliance Inc (NASDAQ:WBA): Ranked #2172 globally with a market cap of $10.37 Billion USD.
- ALIB.HL.INF.TEC.UNSP.ADR (F:TWYA): Ranked #2541 globally with a market cap of $8.42 Billion USD ( €7.20 Billion EUR).
- Raia Drogasil S.A (SA:RADL3): Ranked #2963 globally with a market cap of $6.67 Billion USD ( R$34.01 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #1929 | JD HEALTH INTL LTD | F:8ZN | $12.04 Billion | €3.80 |
| #2172 | Walgreens Boots Alliance Inc | NASDAQ:WBA | $10.37 Billion | $11.98 |
| #2541 | ALIB.HL.INF.TEC.UNSP.ADR | F:TWYA | $8.42 Billion | €8.95 |
| #2963 | Raia Drogasil S.A | SA:RADL3 | $6.67 Billion | R$19.45 |
Scienture Holdings, Inc. Historical Marketcap From 2015 to 2026
Between 2015 and today, Scienture Holdings, Inc.'s market cap moved from $422.10 Million to $ 13.92 Million, with a yearly change of -26.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $13.92 Million | -33.53% |
| 2025 | $20.94 Million | -91.57% |
| 2024 | $248.44 Million | +86.91% |
| 2023 | $132.92 Million | -14.04% |
| 2022 | $154.64 Million | -82.92% |
| 2021 | $905.59 Million | -55.39% |
| 2020 | $2.03 Billion | +380.91% |
| 2019 | $422.10 Million | +266.66% |
| 2018 | $115.12 Million | -33.33% |
| 2017 | $172.67 Million | -2.18% |
| 2016 | $176.51 Million | -58.18% |
| 2015 | $422.10 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Scienture Holdings, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.92 Million USD |
| MoneyControl | $13.92 Million USD |
| MarketWatch | $13.92 Million USD |
| marketcap.company | $13.92 Million USD |
| Reuters | $13.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Scienture Holdings, Inc.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of… Read more